Published

Investigational COMP360 psilocybin treatment for treatment-resistant depression: assessing altered states of consciousness

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2024-01-01
Source: OpenAlex
DOI: 10.1016/j.nsa.2024.104391
PubMed: Unavailable

Authors

N. Hewitt J. Chai-Rees Megan Croal S. Mistry Jeng-Yu Tsai Matthew B. Young Guy M. Goodwin

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Consciousness Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Investigational COMP360 psilocybin treatment for treatment-resistant depression: assessing altered states of consciousness2024-01-01

Related papers

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depressionPsyArXiv · 2026-06-10 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14 Altered States, Enhanced Potential: Psychedelics and Physical PerformancePsyArXiv · 2026-06-12 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12 An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10